These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32991803)

  • 1. Computational Investigation of Gantenerumab and Crenezumab Recognition of Aβ Fibrils in Alzheimer's Disease Brain Tissue.
    Chen Y; Wei G; Zhao J; Nussinov R; Ma B
    ACS Chem Neurosci; 2020 Oct; 11(20):3233-3244. PubMed ID: 32991803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies.
    Zhao J; Nussinov R; Ma B
    J Biol Chem; 2017 Nov; 292(44):18325-18343. PubMed ID: 28924036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.
    Bohrmann B; Baumann K; Benz J; Gerber F; Huber W; Knoflach F; Messer J; Oroszlan K; Rauchenberger R; Richter WF; Rothe C; Urban M; Bardroff M; Winter M; Nordstedt C; Loetscher H
    J Alzheimers Dis; 2012; 28(1):49-69. PubMed ID: 21955818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic Modeling of Soluble Aβ Dynamics and Target Engagement in the Brain by Anti-Aβ mAbs in Alzheimer's Disease.
    Ferl GZ; Fuji RN; Atwal JK; Sun T; Ramanujan S; Quartino AL
    Curr Alzheimer Res; 2020; 17(4):393-406. PubMed ID: 32116192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From monomer to fibril: Abeta-amyloid binding to Aducanumab antibody studied by molecular dynamics simulation.
    Frost CV; Zacharias M
    Proteins; 2020 Dec; 88(12):1592-1606. PubMed ID: 32666627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in Alzheimer's disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline.
    Azargoonjahromi A
    J Pharm Pharmacol; 2024 Sep; 76(9):1115-1131. PubMed ID: 38767981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ.
    Meilandt WJ; Maloney JA; Imperio J; Lalehzadeh G; Earr T; Crowell S; Bainbridge TW; Lu Y; Ernst JA; Fuji RN; Atwal JK
    Alzheimers Res Ther; 2019 Dec; 11(1):97. PubMed ID: 31787113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.
    Bouter Y; Lopez Noguerola JS; Tucholla P; Crespi GA; Parker MW; Wiltfang J; Miles LA; Bayer TA
    Acta Neuropathol; 2015 Nov; 130(5):713-29. PubMed ID: 26467270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
    Lu D; Dou F; Gao J
    Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer's disease.
    Zampar S; Klafki HW; Sritharen K; Bayer TA; Wiltfang J; Rostagno A; Ghiso J; Miles LA; Wirths O
    Neuropathol Appl Neurobiol; 2020 Dec; 46(7):673-685. PubMed ID: 32497293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.
    Söderberg L; Johannesson M; Gkanatsiou E; Nygren P; Fritz N; Zachrisson O; Rachalski A; Svensson AS; Button E; Dentoni G; Osswald G; Lannfelt L; Möller C
    Sci Rep; 2024 May; 14(1):10868. PubMed ID: 38740836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?
    Watt AD; Crespi GA; Down RA; Ascher DB; Gunn A; Perez KA; McLean CA; Villemagne VL; Parker MW; Barnham KJ; Miles LA
    Acta Neuropathol; 2014; 127(6):803-10. PubMed ID: 24803227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
    Boess FG; Scelsi MA; Grimmer T; Perry RJ; Tonietto M; Klein G; Hofmann C; Salami M; Wojtowicz J; Lansdall CJ; Lane C; Kerchner GA; Smith J; Doody RS
    J Prev Alzheimers Dis; 2024; 11(3):537-548. PubMed ID: 38706270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
    Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
    Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid beta 1-40 and 1-42 fibril ratios and maturation level cause conformational differences with minimal impact on autophagy and cytotoxicity.
    Johansson L; Sandberg A; Nyström S; Hammarström P; Hallbeck M
    J Neurochem; 2024 Sep; 168(9):3308-3322. PubMed ID: 39133499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease.
    Yoshida K; Moein A; Bittner T; Ostrowitzki S; Lin H; Honigberg L; Jin JY; Quartino A
    Alzheimers Res Ther; 2020 Jan; 12(1):16. PubMed ID: 31969177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.
    Arndt JW; Qian F; Smith BA; Quan C; Kilambi KP; Bush MW; Walz T; Pepinsky RB; Bussière T; Hamann S; Cameron TO; Weinreb PH
    Sci Rep; 2018 Apr; 8(1):6412. PubMed ID: 29686315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.